- Home
- PTGX vs CRNX Comparison
PTGX vs CRNX Comparison
Compare PTGX & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- CRNX
- Stock Information
- Founded
- PTGX 2006
- CRNX 2008
- Country
- PTGX United States
- CRNX United States
- Employees
- PTGX N/A
- CRNX N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- CRNX Health Care
- Exchange
- PTGX Nasdaq
- CRNX Nasdaq
- Market Cap
- PTGX 3.3B
- CRNX 2.8B
- IPO Year
- PTGX 2016
- CRNX 2018
- Fundamental
- Price
- PTGX $58.97
- CRNX $30.61
- Analyst Decision
- PTGX Strong Buy
- CRNX Strong Buy
- Analyst Count
- PTGX 8
- CRNX 7
- Target Price
- PTGX $70.13
- CRNX $74.33
- AVG Volume (30 Days)
- PTGX 646.3K
- CRNX 1.0M
- Earning Date
- PTGX 08-06-2025
- CRNX 08-07-2025
- Dividend Yield
- PTGX N/A
- CRNX N/A
- EPS Growth
- PTGX N/A
- CRNX N/A
- EPS
- PTGX 0.80
- CRNX N/A
- Revenue
- PTGX $209,180,000.00
- CRNX $1,392,000.00
- Revenue This Year
- PTGX N/A
- CRNX $489.51
- Revenue Next Year
- PTGX $185.11
- CRNX $661.93
- P/E Ratio
- PTGX $73.40
- CRNX N/A
- Revenue Growth
- PTGX N/A
- CRNX 0.51
- 52 Week Low
- PTGX $33.31
- CRNX $24.10
- 52 Week High
- PTGX $61.89
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- PTGX 57.69
- CRNX 56.46
- Support Level
- PTGX $55.26
- CRNX $28.73
- Resistance Level
- PTGX $58.79
- CRNX $31.45
- Average True Range (ATR)
- PTGX 2.20
- CRNX 1.16
- MACD
- PTGX 0.39
- CRNX 0.25
- Stochastic Oscillator
- PTGX 66.84
- CRNX 86.34
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.